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When California voters approved Proposition 64 in 2016, legalizing recreational cannabis for adults, they fundamentally altered the 
state’s cannabis landscape. They also, albeit uninten-
tionally, furnished UC researchers with intriguing 
new avenues of potential inquiry — many of which are 
blocked by federal law and pursuant UC policy. For 
example, researchers interested in the cannabis-derived 
sprays and beverages readily available at California’s re-
tail cannabis establishments cannot obtain those prod-
ucts for research purposes by any permissible means. 
Licensed cannabis businesses dot the state today, but 
cannabis research still operates within the same strict 
constraints that have hindered it since legalization was 
a futile sentiment on a bumper sticker.
Because state law is subordinate to federal law, 
Proposition 64 is subordinate to the 1970 Controlled 
Substances Act. Associated with that act is a “schedul-
ing” apparatus, overseen by the Drug Enforcement 
Administration (DEA), that identifies cannabis as ripe 
for abuse and devoid of medical merit. Thus, along 
with heroin and other Schedule I substances, the 
psychoactive variety of cannabis cannot under federal 
law be cultivated, processed, sold, consumed — or, for 
the most part, researched. (However, change is afoot 
for research on industrial hemp, the non-psychoactive 
variety of cannabis — more on this below.)
The University of California, as a law-abiding insti-
tution, complies with the Controlled Substances Act 
and its nearly total cannabis prohibition. As an institu-
tion that receives federal funding, UC complies with 
the Drug-Free Workplace Act and the Safe and Drug-
Free Schools and Communities Act — which require 
universities, if they wish to receive federal funding, to 
implement policies prohibiting on-campus activities 
such as possession or use of controlled substances. UC 
personnel, including staff, faculty and UC Cooperative 
Extension (UCCE) specialists and advisors, are there-
fore prohibited, in their professional capacities, from 
direct contact with the cannabis plant or its extracts, 
and also from certain types of indirect contact. They 
cannot, for example, visit cannabis cultivation sites 
or advise cannabis growers on topics such as yield 
increases. Researchers can’t even use cannabis or 
cannabis-derived products in medical studies — unless 
they fulfill a rather daunting set of federal (and state) 
requirements. 
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Cannabis is legal in California but illegal in the United States. The plant’s ambiguous status cuts off 
many avenues of cannabis research — but leaves other approaches wide open.
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Though researchers who 
wish to study the cannabis 
plant face strict federal 
constraints, opportunities 
to conduct cannabis 
research are not scarce 
around the UC system.
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Those requirements for medical studies include ob-
taining a Schedule I license from the DEA; submitting 
research protocols for Food and Drug Administration 
(FDA) approval; submitting to the FDA an investi-
gational new drug application (if human subjects are 
involved in the research); and, as a non-federal mat-
ter, gaining the approval of a state entity, the Research 
Advisory Panel of California (housed within the Office 
of the Attorney General). If all goes well, research-
ers can then obtain cannabis or cannabis-derived 
substances from a DEA-licensed cultivator, a DEA-
registered bulk manufacturer or, with a DEA import 
license, a foreign exporter. The only DEA-licensed 
cannabis cultivator is the University of Mississippi, 
which grows the plant under a contract funded by the 
National Institute on Drug Abuse (an entity within 
the Department of Health and Human Services). Bulk 
manufacturers of cannabis products such as tetrahy-
drocannabinol (THC) — the psychoactive component 
in cannabis — include, for example, the Massachusetts-
based life science company MilliporeSigma (until re-
cently, Sigma-Aldrich). Providers of imported cannabis 
products — such as Tilray, a Canadian firm — must be 
based in jurisdictions where such products are legal.
No matter which path researchers choose, the pro-
cess isn’t fast or easy. “You need a patient, dedicated 
team willing to jump through extra hoops at the in-
stitutional, state and federal levels,” says Jeffrey Chen, 
Executive Director of UCLA’s Cannabis Research 
Initiative. Even so, Chen reports, federal restrictions on 
types and sources of cannabis products can prevent re-
searchers from conducting cannabis studies at all. And 
again, only medical researchers are eligible to obtain 
cannabis for research. Those who wish to perform ag-
ronomic studies, for example, are simply out of luck.
For all that, opportunities to research cannabis 
are not scarce around the UC system. Observational 
studies of cannabis users are permissible, though the 
cannabis in question cannot be provided by the uni-
versity and must be consumed off campus. Researchers 
interested in the legal or economic dimensions of 
cannabis, or in cannabis policy, will discover few ob-
stacles in the Controlled Substances Act. Several UC 
researchers are vigorously investigating the environ-
mental consequences of cannabis cultivation — and 
in fact Proposition 64 has effectively expanded the 
scope for such research. According to Ted Grantham, 
a UCCE specialist at UC Berkeley and co-director of 
the UCB Cannabis Research Center, researchers can 
now interact with cannabis growers — to learn, for 
example, about their cultivation practices — in a way 
that grower reluctance previously precluded. Today, 
Grantham reports, “a subset of growers is very inter-
ested in daylighting the cannabis industry to establish 
its legitimacy as an agricultural crop rather than an 
illicit substance.”
In years to come, UC investigators will likely per-
form extensive research on industrial hemp. This form 
of cannabis, which contains extremely small amounts 
of THC, is useless for producing a “high” — but very 
useful for making fabrics, insulation, paper and more. 
Until recently, however, federal law did not distinguish 
between low-THC hemp and high-THC cannabis 
— nor between THC and cannabidiol (CBD), a non-
psychoactive cannabis compound purported to relieve 
medical conditions ranging from arthritis to anxiety.
The legal landscape for hemp and CBD began to 
change on the federal level in 2014, when that year’s 
Farm Bill allowed universities to cultivate industrial 
hemp for research purposes (though UC established 
no such program). In 
June of last year, the FDA 
approved a CBD-based 
medicine for treatment of 
epilepsy-related seizures. 
With last December’s pas-
sage of the 2018 Farm Bill, 
industrial hemp became 
a legal crop — pending 
establishment of a regulatory framework to govern it. 
Hemp-derived CBD now appears on course for com-
plete de-scheduling by the DEA, and the FDA is wres-
tling with how to regulate the CBD-based consumer 
products already hitting the market in many states. 
Amid this liberalization of federal law on hemp and 
CBD, it becomes easy to envision UC academics and 
UCCE personnel performing agronomic studies with 
hemp — and providing California hemp growers with 
the same sort of research-based knowledge that has 
long been available to cultivators of almonds, grapes 
and lettuce. c
— Lucien Crowder
UC researchers are 
vigorously investigating the 
environmental consequences 
of cannabis cultivation.
Cannabis and hemp — what’s the difference?
• Cannabis and industrial hemp are precisely the same plant — Cannabis 
sativa — but they differ in their concentration of the psychoactive 
compound tetrahydrocannabinol (THC).
• Under the stipulations of the 2018 Farm Bill, the THC content of industrial 
hemp may not exceed 0.3% (on a dry-weight basis). Cannabis sativa whose 
THC content exceeds that level is regarded as marijuana by the federal gov-
ernment. (The state of California prefers the scientific term “cannabis” to the 
racially charged term “marijuana.”)
• Psychoactive cannabis is mainly used to produce a “high” — though many 
California consumers use cannabis for medicinal purposes as well. Hemp is 
used for fiber and in diverse industrial applications, and also as a source of 
cannabidiol (CBD, a non-psychoactive compound purported to confer nu-
merous health benefits).
• In the past, hemp was bred mainly for fiber and cannabis was bred to pro-
duce large buds that were rich in THC. The appearance of hemp and can-
nabis plants therefore usually differed. Today, because hemp is often bred 
to produce CBD — concentrated, like THC, in the buds of Cannabis sativa — 
industrial hemp and psychoactive cannabis often differ little in appearance.
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